Compare INSE & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSE | ALXO |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 205.9M |
| IPO Year | 2014 | 2020 |
| Metric | INSE | ALXO |
|---|---|---|
| Price | $6.03 | $1.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $14.00 | $3.50 |
| AVG Volume (30 Days) | 116.3K | ★ 951.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $199,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.25 | N/A |
| 52 Week Low | $5.95 | $0.80 |
| 52 Week High | $9.95 | $2.66 |
| Indicator | INSE | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 30.68 | 48.50 |
| Support Level | N/A | $1.93 |
| Resistance Level | $8.42 | $2.21 |
| Average True Range (ATR) | 0.31 | 0.13 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 0.78 | 33.34 |
Inspired Entertainment Inc is a gaming technology company, supplying content, platform and other products and services to licensed online and land-based lottery, betting and gaming operators of various countries through a range of distribution channels, on a business-to-business basis. The company provides digital gaming solutions (i) on its own proprietary and secure network, which accommodates a wide range of devices, including land-based gaming machine terminals, mobile devices and online computer applications, and (ii) through third party networks. It operates in four business segments: Gaming, Virtual Sports, Interactive and Leisure. The majority of revenue is derived from the Leisure Segment, which includes the supply of the gaming and amusement machines.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.